X0609 4 2026-05-04 0001124105 GYRE THERAPEUTICS, INC. GYRE 0001958487 Eastling Thomas Wilson false C/O GYRE THERAPEUTICS, INC. 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 true Chief Financial Officer false Stock Option (Right to Buy) 0.32 2026-05-04 4 A 0 95060 0 A 2028-06-07 Common Stock 95060 95060 D Stock Option (Right to Buy) 0.93 2026-05-04 4 A 0 47530 0 A 2030-01-12 Common Stock 47530 47530 D Stock Option (Right to Buy) 2 2026-05-04 4 A 0 11882 0 A 2030-12-17 Common Stock 11882 11882 D Stock Option (Right to Buy) 2 2026-05-04 4 A 0 33271 0 A 2031-06-09 Common Stock 33271 33271 D Stock Option (Right to Buy) 2.34 2026-05-04 4 A 0 95060 0 A 2032-01-23 Common Stock 95060 95060 D Stock Option (Right to Buy) 5.98 2026-05-04 4 A 0 92683 0 A 2034-11-12 Common Stock 92683 92683 D Stock Option (Right to Buy) 0.32 2026-05-04 4 A 0 33271 0 A 2028-06-07 Common Stock 33271 33271 I By Spouse This option is fully vested. This option represents a right to purchase 92,683 shares of the Issuer's common stock, one quarter of which vested on November 13, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Exhibit 24 - Power of Attorney /s/ Thomas Eastling 2026-05-06